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nderstanding the Role of
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oronary Artery Lesion
rogression, and
n-Stent Restenosis*
obbert J. De Winter, MD, PHD, Margo Klomp, MD
msterdam, the Netherlands
one marrow-derived, circulating endothelial progenitor
ells (EPCs) were first described by Asahara et al. (1) in
997. They discovered that EPCs have regenerative capac-
ties and play an important role in vessel wall homeostasis.
hereas animal studies have shown that these progenitor
ells beneficially influence the repair of endothelial cells after
njury and the progression of atherosclerosis (2,3), the role
f EPCs in humans is less well understood.
See page 78
In subjects with cardiovascular risk factors, such as
ypertension and diabetes mellitus, studies have shown that
he number of circulating EPCs is reduced, and their
unction adversely affected (4,5). In contrast, elevated EPC
evels were seen in patients that suffered an acute myocardial
nfarction (6) and patients that underwent a percutaneous
oronary intervention (PCI) (7). Unfortunately, studies
eporting on the number of circulating EPCs in patients
ith coronary artery disease (CAD) fail to show agreement.
ome studies report that the EPC number is reduced in
atients with atherosclerotic disease (8,9), whereas other
tudies report that EPC levels are indeed increased in CAD
atients (10,11). There is accumulating evidence that a
educed number of EPCs is associated with the occurrence
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From Academic Medical Center, University of Amsterdam, Amsterdam, the
etherlands. The Academic Medical Center Amsterdam coordinates the TRIAS
TRI-Stent Adjudication Study) Program, an independent investigator-initiateds
tudy, for which it receives research support from OrbusNeich Medical Technologies
nc.f ischemic cardiovascular events in patients with angio-
raphically documented CAD (12,13).
Further assessment of circulating EPCs as surrogate
iological markers might be helpful to identify novel
herapeutic approaches to enhance endogenous vascular
epair and favorably modify the progression of cardiovas-
ular disease. The establishment of a healthy, functional
ndothelial layer may not only improve vascular homeostasis,
ut by abluminal secretion of anti-inflammatory and antipro-
iferative factors may also reduce neointimal formation follow-
ng stent placement. Currently, the novel bioengineered
enous Endothelial Progenitor Cell Capturing Stent
OrbusNeich Medical Technologies Inc., Fort Lauder-
ale, Florida) coated with antihuman CD34 antibodies
ttracting circulating EPCs is available in many countries
or the treatment of patients with clinically significant
AD (14). Animal studies have shown that after only 60
in of incubation, a confluent monolayer of adherent
D34 cells was formed covering the stent struts (15–
7). In 2 small nonrandomized studies (HEALING–
IM [Healthy Endothelial Accelerated Lining Inhibits
eointimal Growth–First In Man] and HEALING II
tudies), the safety and efficacy of the EPC-capturing
tent was demonstrated in patients with noncomplex
oronary artery lesions. The multicenter, randomized
RIAS (TRI-Stent Adjudication Study) program is on-
oing, in which the EPC capturing stent is compared to
rug-eluting stents and bare-metal stents and in which
PCs before PCI will also be measured (18).
The number of circulating EPCs can be measured using
uorescence-activated cell-sorting analysis and standard
ating techniques to detect surface marker expression. The
PCs’ function can, in part, be measured by assessing their
olony forming capacity in vitro (19). Modalities to increase
he number or improve the function of EPCs may be
romising in the treatment of atherosclerotic disease.
mong these are physical exercise, administration of eryth-
opoietin and treatment with statins (which enhance both
he number and functionality of EPCs). In addition, local
dministration and systemic transfusion of vascular progen-
tor cells improves endothelial function and reduces athero-
clerosis in animal models (20,21).
However, much remains to be clarified, including how
hese cells are characterized. For example, in 1 study (22)
ollowing angioplasty, level of circulating EPCs with a
unctional phenotype increases, whereas no increase is seen
n the putative progenitor cells (CD34KDR) as charac-
erized by surface marker expression, questioning whether
hese represent the same cell populations. In addition, in a
ecent large population study (23), hypertension, glycosy-
ated hemoglobin, and plasma triglycerides were positively
orrelated with circulating EPC numbers, and the investi-
ators speculated this may represent a protective, compen-
atory response.
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88In this issue of JACC: Cardiovascular Interventions, Pelliccia
t al. (24) examined the relationship between endothelial
rogenitor cells (CD34KDR and CD133KDR), cells
rom the monocyte/macrophage lineage (CD45CD14),
nd angiographic outcome at 8 months. A total of 155
onsecutive patients with stable angina underwent PCI with a
are-metal stent, and 20 healthy controls without CAD were
lso studied. At 8-month follow-up, the patients were subdi-
ided in 3 groups based on their angiographic characteristics:
atients without progression of CAD and without in-stent
estenosis (n  103), patients with progression of coronary
therosclerosis (n  22), and patients with in-stent restenosis
n  30). The number of cells in each cell population was
rospectively measured the day before PCI and correlated with
uantitative coronary angiographic assessments of in-stent
estenosis and lesion progression on follow-up angiograms. No
ignificant differences among the groups were found regarding
he baseline clinical and angiographic characteristics although
he overall and subdivided subject numbers were all small.
bsolute numbers of EPCs, both CD34/KDRCD45–
nd CD133/KDR/CD45–, were higher in patients with
n-stent restenosis than in patients without in-stent restenosis
nd controls. In addition, the number of CD14/CD45
ells was higher in patients with restenosis than in patients with
esion progression, patients in the stable CAD group, and in
he control group. In contrast to previous (cross-sectional)
tudies, there was no significant difference in levels of EPCs
etween those with CAD and normal controls. Pelliccia et al.
24) concluded that patients who develop restenosis after
are-metal stent placement have higher baseline numbers of
ubpopulations of EPCs that incorporate into endothelial cells
r play a role in arteriogenesis compared with controls and
atients with either progression of coronary atherosclerosis or
table disease. Specifically regarding the development of in-
tent restenosis, the investigators speculate that an abnormal
ngraftment of CD34 and CD133EPCs causing excessive
ntima proliferation and in-stent restenosis may occur partic-
larly among patients who have greater levels of EPCs at time
f PCI. The results of Pelliccia et al. (24) are in contrast to
hose from previous reports (25-27) on patients treated with
he EPC-attracting Genous stent. In 1 study, Duckers et al.
27) observed that decreased in-stent late lumen loss was
ssociated with higher levels of circulating EPCs. These
nterstudy differences may be explained by distinctions in study
esigns or cell populations measured. In the study by Duckers
t al. (27), EPCs were assessed 6 months following PCI, no
are-metal stents were used, and the cells identified as EPCs
ere 7AAD–/CD45/CD34/KDR, so-called viable
PCs.
Considering these and other varied observations, one
ould conclude that despite meaningful investigations, the
iology and clinical significance of EPCs in cardiovascular
isease remain poorly understood. It is possible, for exam-
le, that the CD34 population may be composed ofrecursors of both endothelial and fibroblast phenotypes. It
s also illustrative that there is not a uniform unit of measure
hen assessing the number of circulating EPCs. In different
tudies, the number of EPCs has been expressed as number
f cells per 1,000 white blood cells, percentage per 100
eripheral mononuclear cells, fluorescence-activated cell-
orting events per 10,000 counts, number of cells per 1 l,
r viable EPCs per 100 l. Again comparing the studies by
elliccia et al. (24) and Duckers et al. (27), even though
oth included similar patients with stable angina, there is a
everal-hundred-fold difference in the number of EPCs
eported. It is also not know if it is the CD34/KDR/
D45– cells, the CD133/KDR/CD45– cells, or other
ells that are responsible for colony forming in the func-
ional colony forming unit (Hill) assay (4).
In summary, Pelliccia et al. (24) conclude that patients
ith restenosis have higher numbers of subpopulations of
PCs than control patients and patients with either pro-
ression of coronary atherosclerosis or stable disease. These
esults are appreciated and hopefully will be followed by
bservations from other investigators. For the future, several
reas must be further pursued, including the characteriza-
ion of bone marrow-derived circulating EPCs and sub-
opulations; the determination of factors that influence
heir number, function, and biological significance, both in
ealthy subjects and in patients with cardiovascular disease;
nd the standardization of measurements and units of
easure to interpret results from different laboratories.
eprint requests and correspondence: Prof. Dr. Robbert J. De
inter, Department of Cardiology, B2-137, Academic Medical
enter, University of Amsterdam, PO Box 22660, 1100DD,
msterdam, the Netherlands. E-mail: r.j.dewinter@amc.uva.nl.
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